<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - RANIBIZUMAB</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>RANIBIZUMAB</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#nationalFunding" data-toggle="tab">National funding/access decisions</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#conceptionAndContraception" data-toggle="tab">conception and contraception</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Neovascular (wet) age-related macular degeneration (specialist use only)</span>,
            </h4>
            <p class="specificity"><span class="route">By intravitreal injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                500 micrograms once a month, to be administered into the affected eye, monitor visual acuity monthly, continue treatment until visual acuity is stable for 3 consecutive months, thereafter monitor visual acuity monthly, if necessary subsequent doses may be given at least 1 month apart.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Diabetic macular oedema</span>,
                <span class="indication">Macular oedema secondary to retinal vein occlusion (specialist use only)</span>,
            </h4>
            <p class="specificity"><span class="route">By intravitreal injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 500 micrograms once a month, to be administered into the affected eye, monitor visual acuity monthly, continue treatment until visual acuity is stable for 3 consecutive months (discontinue treatment if no improvement in visual acuity after initial 3 injections), thereafter monitor visual acuity monthly, if necessary subsequent doses may be given at least 1 month apart.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Choroidal neovascularisation secondary to pathologic myopia (specialist use only)</span>,
            </h4>
            <p class="specificity"><span class="route">By intravitreal injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 500 micrograms, to be administered as a single injection into the affected eye, monitor for disease activity monthly for first 2 months, then at least every 3 months thereafter during the first year, then as required, if necessary subsequent doses may be given at least 1 month apart.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Concomitant treatment of diabetic macular oedema, or macular oedema secondary to branch retinal vein occlusion, with laser photocoagulation (specialist use only)</span>,
            </h4>
            <p class="specificity"><span class="route">By intravitreal injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                500 micrograms, to be administered at least 30 minutes after laser photocoagulation.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Manufacturer advises avoid unless potential benefit outweighs risk.</p>
            </section>
      </section>



      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>Ocular or periocular infection</li>
            <li>severe intra-ocular inflammation</li>
            <li>signs of irreversible ischaemic visual function loss in patients with retinal vein occlusion</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Allergic skin reactions, anaemia, anterior chamber flare, anxiety, arthralgia, blepharitis, cataract, conjunctival disorders, conjunctivitis, cough, eye haemorrhage, eyelid oedema, headache, iridocyclitis, iritis, nasopharyngitis, nausea, ocular discomfort, photophobia, photopsia, posterior capsule opacification, punctuate keratitis, raised intra-ocular pressure, retinal disorders, urinary tract infection, uveitis, visual disturbance, vitreous disorders,
              </p>
              <p>
                <strong>uncommon:</strong> Blindness, corneal disorders, hyphaema, hypopyon, iris adhesion, keratopathy,
              </p>
        
        
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <p>For further information on administration, consult product literature.</p>
            </section>
      </section>


      <section class="tab-pane" id="nationalFunding">
        <h2>National funding/access decisions</h2>

            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA155</h3>
              <p outputclass="title">Ranibizumab and pegaptanib for the treatment of age-related macular degeneration (updated May 2012)</p> <p>Ranibizumab is recommended for the treatment of wet age-related macular degeneration if all of the following apply:</p> <ul> <li>the best corrected visual acuity is between 6/12 and 6/96;</li> <li>there is no permanent structural damage to the central fovea;</li> <li>the lesion size is less than or equal to 12 disc areas in greatest linear dimension;</li> <li>there is evidence of recent disease progression;</li> <li>the manufacturer provides ranibizumab with the discount agreed in the patient access scheme (as revised in 2012).</li> </ul> <p>Ranibizumab should only be continued in patients who maintain adequate response to therapy.</p><xref format="html" href="http://www.nice.org.uk/TA155">www.nice.org.uk/TA155</xref>
                <a href="http://www.nice.org.uk/TA155" target="_blank">www.nice.org.uk/TA155</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA274</h3>
              <p outputclass="title">Ranibizumab for the treatment of diabetic macular oedema (February 2013)</p> <p>Ranibizumab is recommended as an option for the treatment of visual impairment due to diabetic macular oedema only if:</p> <ul> <li> the eye has a central retinal thickness of 400&#8239;micrometres or more at the start of treatment <b>and</b> </li> <li>the manufacturer provides ranibizumab with the discount agreed in the patient access scheme (as revised in 2012).</li> </ul> <p>Patients currently receiving ranibizumab for treating visual impairment due to diabetic macular oedema whose disease does not meet the criteria should be able to continue treatment until they and their clinician consider it appropriate to stop.</p><xref format="html" href="http://www.nice.org.uk/TA274">www.nice.org.uk/TA274</xref>
                <a href="http://www.nice.org.uk/TA274" target="_blank">www.nice.org.uk/TA274</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA283</h3>
              <p outputclass="title">Ranibizumab for the treatment of visual impairment caused by macular oedema secondary to retinal vein occlusion (May 2013)</p> <p>Ranibizumab is recommended as an option for treating visual impairment caused by macular oedema:</p> <ul> <li>following central retinal vein occlusion <b>or</b> </li> <li>following branch retinal vein occlusion only if treatment with laser photocoagulation has not been beneficial, or when laser photocoagulation is not suitable because of the extent of macular haemorrhage <b>and</b> </li> <li>only if the manufacturer provides ranibizumab with the discount agreed in the patient access scheme revised in the context of NICE technology appraisal guidance 274.</li> </ul><xref format="html" href="http://www.nice.org.uk/TA283">www.nice.org.uk/TA283</xref>
                <a href="http://www.nice.org.uk/TA283" target="_blank">www.nice.org.uk/TA283</a>
            </section>
            <section class="niceTechnologyAppraisals">
              <h3 class="fundingIdentifier">NICE TA298</h3>
              <p outputclass="title">Ranibizumab for treating choroidal neovascularisation associated with pathological myopia (November 2013)</p> <p>Ranibizumab is recommended as an option for treating visual impairment due to choroidal neovascularisation secondary to pathological myopia when the manufacturer provides ranibizumab with the discount agreed in the patient access scheme.</p><xref format="html" href="http://www.nice.org.uk/TA298">www.nice.org.uk/TA298</xref>
                <a href="http://www.nice.org.uk/TA298" target="_blank">www.nice.org.uk/TA298</a>
            </section>
      </section>


      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Active systemic infection
          </li>
          <li>
            diabetic macular oedema due to type 1 diabetes (limited information available)
          </li>
          <li>
            diabetic patients with HbA<sub>1c </sub> over 12%
          </li>
          <li>
            history of stroke
          </li>
          <li>
            history of transient ischaemic attack
          </li>
          <li>
            patients at risk of retinal pigment epithelial tear
          </li>
          <li>
            previous intravitreal injections
          </li>
          <li>
            proliferative diabetic retinopathy
          </li>
          <li>
            retinal detachment or macular hole (discontinue treatment if rhegmatogenous retinal detachment or stage 3 or 4 macular holes develop)
          </li>
          <li>
            uncontrolled hypertension
          </li>
        </ul>
        <ul>
          <li>
            <p>Ranibizumab is given by intravitreal injection by specialists. There is a potential risk of arterial thromboembolic events and non-ocular haemorrhage following the intravitreal injection of vascular endothelial growth factor inhibitors. Endophthalmitis can occur after intravitreal injections&#8212;patients should be advised to report any signs of infection immediately.</p>
          </li>
        </ul>
      </section>

      <section class="tab-pane" id="conceptionAndContraception">
        <h2>Advice regarding conception and contraception</h2>

            <section class="generalInformation">
              <p>Manufacturer recommends women use effective contraception during and for at least 3 months after treatment.</p>
            </section>
      </section>

      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>Monitor intra-ocular pressure, perfusion of the optic nerve head, and for signs of ocular infection following injection.</p><p>Monitor visual acuity, see individual indications and dose for frequency.</p>
            </section>
      </section>











      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of RANIBIZUMAB</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP77495"><a href="../medicinalForm/PHP77495.html" data-target="#PHP77495" data-action="load">Solution for injection</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
